Challenging a Misnomer? The Role of Inflammatory Pathways in Inflammatory Breast Cancer by Riley J. Morrow, Nima Etemadi, Belinda Yeo, Matthias Ernst

“…The more aggressive triple-negative and HER2-positive breast cancer subtypes are overrepresented in inflammatory breast cancer compared with noninflammatory breast cancer, with a poorer prognosis in response to conventional therapies. …”
Get full text

Stem cell markers: A guide to neoadjuvant therapy in breast carcinomas by Zuhal Gucin, Nur Buyukpinarbasili, Melin Ozgun Gecer, Yeliz Emine Ersoy, Haci Mehmet Turk, Seyma Yildiz, Direnc Ozlem Aksoy

“…Results: Histologically high-grade tumors are more common in the near-complete/complete response group (P = 0.004). HER2-positive tumors were more common in the complete/near-complete response group (P = 0.054). …”
Get full text

Characterisation of IGF-1 (rs7136446) and IL-6 (rs1800795) polymorphisms among breast cancer patients in western Algeria by Fatima Zohraa Boussouf, Asmahane Medjdoub, Zineb Tahari, Moussa Messatfa, Noria Bouras, Chahinez Amira Dahmani, Sonia Amal Seddiki, Tewfik Sahraoui

“…The results showed that IGF-1 rs7136446 was positively associated with BC (p = 0.00001) and that the distribution of genotype frequencies of rs7136446 showed a statistically difference between human epidermal growth factor receptor 2 (HER-2) positive and HER-2 negative BC (p = 0.04), but this association did not last after the correction of Bonferroni. …”
Get full text

Resveratrol, Acetyl-Resveratrol, and Polydatin Exhibit Antigrowth Activity against 3D Cell Aggregates of the SKOV-3 and OVCAR-8 Ovarian Cancer Cell Lines by Simon J. Hogg, Kenny Chitcholtan, Wafaa Hassan, Peter H. Sykes, Ashley Garrill

“…The purpose of this study was to investigate and compare any potential antigrowth effects of resveratrol and two of its derivatives, acetyl-resveratrol and polydatin, on 3D cell aggregates of the EGFR/Her-2 positive and negative ovarian cancer cell lines SKOV-3 and OVCAR-8, respectively. …”
Get full text

Monitoring and management of adverse effects associated with trastuzumab deruxtecan: a UAE-specific consensus by Emad Dawoud, Fathi Azribi, Aref Chehal, Shaheenah Dawood, Syed Hammad Tirmazy, Dina Hamza, Hassan Jaafar, Hussam Marashi

“…Although initially developed to target HER2-positive breast cancer, trastuzumab deruxtecan (T-DXd), an ADC, has now also been approved to treat metastatic or unresectable HER2-low breast cancers. …”
Get full text

Therapeutic strategies for fungating and ulcerating breast cancers: A systematic review and narrative synthesis by Valentina Zagardo, Mandara Harikar, Gianluca Ferini

“…We found that treatment modalities increased, from an average of two in luminal-B cancers to three in HER2-positive cases, with over half achieving complete response. …”
Get full text

Association of One-Step Nucleic Acid Amplification Detected Micrometastases with Tumour Biology and Adjuvant Chemotherapy by Ghaleb Goussous, Sadaf Jafferbhoy, Niamh Smyth, Lisette Hammond, Sankaran Narayanan, Robert Mark Kirby, Soni Soumian

“…In the OSNA group, there was also a proportional increase in Grade III, triple-negative, ER-negative, and HER-2-positive tumours being diagnosed with micrometastases. …”
Get full text

Therapeutic Targeting of Fibroblast Growth Factor Receptors in Gastric Cancer by Mikito Inokuchi, Yoshitaka Fujimori, Sho Otsuki, Yuya Sato, Masatoshi Nakagawa, Kazuyuki Kojima

“…Many molecular-targeted therapies inhibiting signaling pathways of various tyrosine kinase receptors have been developed, and monoclonal antibodies targeting human epidermal growth factor receptor 2 (HER2) have become standard therapy for HER2-positive GC. An inhibitor of vascular endothelial growth factor receptor 2 or MET has also produced promising results in patients with GC. …”
Get full text

Omega-3 fatty acids: molecular weapons against chemoresistance in breast cancer by Vittoria Marchio, Giuseppina Augimeri, Catia Morelli, Adele Vivacqua, Cinzia Giordano, Stefania Catalano, Diego Sisci, Ines Barone, Daniela Bonofiglio

“…Highly targeted therapies have been developed for different subtypes of breast cancer, including hormone receptor (HR)-positive and human epidermal growth factor receptor 2 (HER2)-positive breast cancer. However, triple-negative breast cancer (TNBC) and metastatic breast cancer disease are primarily treated with chemotherapy, which improves disease-free and overall survival, but does not offer a curative solution for these aggressive forms of breast cancer. …”
Get full text

Targeted therapy and immunotherapy for gastric cancer: rational strategies, novel advancements, challenges, and future perspectives by Dong Luo, Yunmei Liu, Zhengmao Lu, Lei Huang

“…In particular, markable breakthroughs have been made in HER2-targeting drugs for HER2-positive GC patients. To address intrinsic and acquired resistances to HER2-targeting drugs, novel therapeutic agents including bispecific antibodies and antibody–drug conjugates (ADC) targeting HER2 have been developed. …”
Get full text

Impact of adjuvant trastuzumab therapy and its discontinuation on cardiac function and mortality in patients with early-stage breast cancer: An analysis based on the Japanese Recei... by Keiko Miyazato, Hiroshi Ohtsu, Akihiko Shimomura, Naohiro Yonemoto, Chikako Shimizu, Kazuhiro Sase, Shinichiro Ueda

“…Standard trastuzumab therapy can reduce the risk of early recurrence of HER2-positive breast cancer. However, trastuzumab-induced cardiac dysfunction may force the discontinuation of adjuvant trastuzumab therapy. …”
Get full text

Investigating the role of cathepsins in breast cancer progression: a Mendelian randomization study by Shengyi Zhou, Shengyi Zhou, Shengyi Zhou, Yizhou Sun, Yizhou Sun, Wenzhang Zha, Wenzhang Zha, Guangjun Zhou, Guangjun Zhou

“…Cathepsin E can mediate the effects of APBB1IP, NT5C3B, and ZNF66 on HER2-negative breast cancer, as well as the effects of DHRS9, CDK12, and CD247 on HER2-positive breast cancer. Cathepsin F can mediate the effects of ANXA2R and ZNF605 on in situ breast cancer. …”
Get full text

HER2-related biomarkers predict clinical outcomes with trastuzumab deruxtecan treatment in patients with HER2-expressing metastatic colorectal cancer: biomarker analyses of DESTINY... by Salvatore Siena, Kanwal Raghav, Toshiki Masuishi, Kensei Yamaguchi, Tomohiro Nishina, Elena Elez, Javier Rodriguez, Ian Chau, Maria Di Bartolomeo, Hisato Kawakami, Fumitaka Suto, Makito Koga, Koichiro Inaki, Yusuke Kuwahara, Issey Takehara, Daniel Barrios, Kojiro Kobayashi, Axel Grothey, Takayuki Yoshino

“…The present exploratory biomarker analysis aims to investigate relationships between biomarkers and clinical outcomes in patients with HER2-positive (immunohistochemistry [IHC] 3+ or IHC 2+ and in situ hybridization [ISH] positive) Cohort A (N = 53) of DESTINY-CRC01. …”
Get full text

Inhibition of TFF3 synergizes with c-MET inhibitors to decrease the CSC-like phenotype and metastatic burden in ER+HER2+ mammary carcinoma by Chuyu He, Xuejuan Wang, Yi-Shiou Chiou, Basappa Basappa, Tao Zhu, Vijay Pandey, Peter E. Lobie

“…Abstract The interaction between HER2 and ERα signaling pathways contributes to resistance to anti-estrogen and HER2-targeted therapies, presenting substantial treatment challenges in ER-positive (ER+) HER2-positive (HER2+) mammary carcinoma (MC). Trefoil Factor-3 (TFF3) has been reported to mediate resistance to both anti-estrogen and anti-HER2 targeted therapies in ER+ and ER+HER2+ MC, respectively. …”
Get full text

A Novel Bimodal Imaging Agent Targeting HER2 Molecule of Breast Cancer by Wei Lv, Yamei Shen, Hengli Yang, Rui Yang, Wenbin Cai, Jian Zhang, Lijun Yuan, Yunyou Duan, Li Zhang

“…IR783-NBs-Affibody was able to automatically accumulate on BT474 cells with a highly increased targeting rate of 85.4% compared with previous NBs-Affibody of 26.6%, while Affibody-guided HER2 binding was only found in HER2-positive cell lines (BT474 and T-47D). The newly developed IR783-NBs-Affibody is characterized with favorable HER2 targeting ability and bimodal imaging capability for breast cancer. …”
Get full text

Evaluation of the Expression of the Human Epithelial Receptor 2 (HER2) in Gastric Carcinoma by Roberto de Moraes Cordts Filho, Paulo Kassab, Laura Carolina Lopez Claro, Mabel Tatty de Medeiros Fracassi, Patrícia Colombo-Souza, Daniel Kenji Fukuhara, Fábio Rodrigues Thuler, Wilson Rodrigues de Freitas Junior, Elias Jirjoss Ilias, Carlos Alberto Malheiros

“…The immunohistochemistry revealed that 4 patients (3,3%) were HER2-positive, 6 patients (4,9%) HER2-undetermined, and 111 patients (91,7%) HER2-negative. …”
Get full text

Comparison of HER2-Targeted Antibodies for Fluorescence-Guided Surgery in Breast Cancer by Solmaz AghaAmiri, Jo Simien, Alastair M. Thompson, Julie Voss, Sukhen C. Ghosh, Servando Hernandez Vargas, Sarah Kim, Ali Azhdarinia, Hop S. Tran Cao

“…Although therapeutic advances have led to enhanced survival in patients with human epidermal growth factor receptor 2 (HER2)-positive breast cancer, detection of residual disease remains challenging. …”
Get full text

Meta-analysis of the association between overexpression of RAD51 family genes and prognosis and clinical features in breast cancer by Yong-Cheng Liu, Jun Shen

“…Regarding clinical characteristics, high expression of RAD51 family genes was significantly associated with human epidermal growth factor receptor 2 (HER2) positivity [OR = 1.782, 95%CI (1.328–2.392), P < 0.01]. …”
Get full text

CD36 inhibition enhances the anti-proliferative effects of PI3K inhibitors in PTEN-loss anti-HER2 resistant breast cancer cells by You-Yu Liu, Wei-Lun Huang, Sin-Tian Wang, Hui-Ping Hsu, Tzu-Ching Kao, Wei-Pang Chung, Kung-Chia Young

“…Abstract Background HER2-positive patients comprise approximately 20% of breast cancer cases, with HER2-targeted therapy significantly improving progression-free and overall survival. …”
Get full text

Enhanced preoperative prediction of breast lesion pathology, prognostic biomarkers, and molecular subtypes using multiple models diffusion-weighted MR imaging by Litong He, Feng Li, Yanjin Qin, Yuling Li, Qilan Hu, Zhiqiang Liu, Yunfei Zhang, Tao Ai

“…Significant differences in IVIM-D, IVIM-D*, and DKI-MK values were observed between human epidermal growth factor receptor 2 (HER2)-negative and HER2-positive tumors. Furthermore, higher SEM-α and CTRW-β values, along with lower DKI-MD and SEM-DDC values, were noted in the high Ki-67 expression group compared to the low Ki-67 group (p < 0.05). …”
Get full text